Cosciens Biopharma Stock Performance

CSCI Stock   2.03  0.03  1.46%   
The firm shows a Beta (market volatility) of 3.83, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, COSCIENS Biopharma will likely underperform. COSCIENS Biopharma currently shows a risk of 14.58%. Please confirm COSCIENS Biopharma semi variance, and the relationship between the maximum drawdown and rate of daily change , to decide if COSCIENS Biopharma will be following its price patterns.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days COSCIENS Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental indicators, COSCIENS Biopharma is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more

Actual Historical Performance (%)

One Day Return
0.49
Ten Year Return
(65.67)
All Time Return
(65.67)
Last Split Factor
1:4
Last Split Date
2024-05-03
1
Why COSCIENS Biopharma Inc. stock remains undervalued - Trade Ideas Consistent Growth Equity Picks - fcp.pa.gov.br
11/05/2025
2
Is COSCIENS Biopharma Inc. stock a safe investment in uncertain markets - Trade Volume Report AI Powered BuySell Recommendations - newser.com
11/10/2025
3
COSCIENS Biopharma Inc. Announces Leadership Change
11/14/2025
4
Long Term Trading Analysis for - news.stocktradersdaily.com
12/04/2025
5
Why COSCIENS Biopharma Inc. stock could be next big winner - Trade Exit Summary Smart Investment Allocation Insights - DonanmHaber
12/19/2025
6
Meet CSCI The First Family of Florida Shell Construction
01/08/2026
7
Value Recap What is COSCIENS Biopharma Incs revenue forecast - Weekly Investment Report Entry Point Confirmation Alerts - baoquankhu1.vn
01/12/2026
Begin Period Cash Flow6.7 M
Total Cashflows From Investing Activities25.1 M

COSCIENS Biopharma Relative Risk vs. Return Landscape

If you would invest  357.00  in COSCIENS Biopharma on November 1, 2025 and sell it today you would lose (154.00) from holding COSCIENS Biopharma or give up 43.14% of portfolio value over 90 days. COSCIENS Biopharma is currently generating 0.0678% in daily expected returns and assumes 14.5844% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than COSCIENS, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days COSCIENS Biopharma is expected to generate 19.4 times more return on investment than the market. However, the company is 19.4 times more volatile than its market benchmark. It trades about 0.0 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.08 per unit of risk.

COSCIENS Biopharma Target Price Odds to finish over Current Price

The tendency of COSCIENS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.03 90 days 2.03 
about 79.77
Based on a normal probability distribution, the odds of COSCIENS Biopharma to move above the current price in 90 days from now is about 79.77 (This COSCIENS Biopharma probability density function shows the probability of COSCIENS Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 3.83 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, COSCIENS Biopharma will likely underperform. Additionally COSCIENS Biopharma has an alpha of 0.4667, implying that it can generate a 0.47 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   COSCIENS Biopharma Price Density   
       Price  

Predictive Modules for COSCIENS Biopharma

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as COSCIENS Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of COSCIENS Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.102.0316.50
Details
Intrinsic
Valuation
LowRealHigh
0.102.0316.50
Details
Naive
Forecast
LowNextHigh
0.042.0416.50
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.612.212.81
Details

COSCIENS Biopharma Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. COSCIENS Biopharma is not an exception. The market had few large corrections towards the COSCIENS Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold COSCIENS Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of COSCIENS Biopharma within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.47
β
Beta against Dow Jones3.83
σ
Overall volatility
0.54
Ir
Information ratio 0.04

COSCIENS Biopharma Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of COSCIENS Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for COSCIENS Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
COSCIENS Biopharma had very high historical volatility over the last 90 days
COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 13.78 M. Net Loss for the year was (15.31 M) with profit before overhead, payroll, taxes, and interest of 4.42 M.
COSCIENS Biopharma generates negative cash flow from operations
Latest headline from news.google.com: Value Recap What is COSCIENS Biopharma Incs revenue forecast - Weekly Investment Report Entry Point Confirmation Alerts - baoquankhu1.vn

COSCIENS Biopharma Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of COSCIENS Stock often depends not only on the future outlook of the current and potential COSCIENS Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. COSCIENS Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding2.6 M
Cash And Short Term Investments16.4 M

COSCIENS Biopharma Fundamentals Growth

COSCIENS Stock prices reflect investors' perceptions of the future prospects and financial health of COSCIENS Biopharma, and COSCIENS Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on COSCIENS Stock performance.

About COSCIENS Biopharma Performance

By evaluating COSCIENS Biopharma's fundamental ratios, stakeholders can gain valuable insights into COSCIENS Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if COSCIENS Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if COSCIENS Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 161.73  123.23 
Return On Tangible Assets(0.39)(0.41)
Return On Capital Employed(0.85)(0.89)
Return On Assets(0.39)(0.41)
Return On Equity(1.34)(1.40)

Things to note about COSCIENS Biopharma performance evaluation

Checking the ongoing alerts about COSCIENS Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for COSCIENS Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
COSCIENS Biopharma had very high historical volatility over the last 90 days
COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 13.78 M. Net Loss for the year was (15.31 M) with profit before overhead, payroll, taxes, and interest of 4.42 M.
COSCIENS Biopharma generates negative cash flow from operations
Latest headline from news.google.com: Value Recap What is COSCIENS Biopharma Incs revenue forecast - Weekly Investment Report Entry Point Confirmation Alerts - baoquankhu1.vn
Evaluating COSCIENS Biopharma's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate COSCIENS Biopharma's stock performance include:
  • Analyzing COSCIENS Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether COSCIENS Biopharma's stock is overvalued or undervalued compared to its peers.
  • Examining COSCIENS Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating COSCIENS Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of COSCIENS Biopharma's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of COSCIENS Biopharma's stock. These opinions can provide insight into COSCIENS Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating COSCIENS Biopharma's stock performance is not an exact science, and many factors can impact COSCIENS Biopharma's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for COSCIENS Stock analysis

When running COSCIENS Biopharma's price analysis, check to measure COSCIENS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSCIENS Biopharma is operating at the current time. Most of COSCIENS Biopharma's value examination focuses on studying past and present price action to predict the probability of COSCIENS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSCIENS Biopharma's price. Additionally, you may evaluate how the addition of COSCIENS Biopharma to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing